Myriad Genetics (MYGN) Reports In-Line Q3 EPS

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $167.3 million versus the consensus estimate of $165.04 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Intercontinental Exchange (ICE) PT Lowered to $208 at Raymond James, 'we view the risk/reward as attractive'
• Morgan Stanley Comments on Tesla (TSLA) Miam Robotaxi Launch